Katie Ditmore

Katie Ditmore is an experienced executive in analytics and insights, currently serving as Executive Director at Revolution Medicines from April 2024 to August 2025, having previously held the position of Senior Director, Analytics and Insights. Prior to this, Katie was Senior Director of New Product Planning at IGM Biosciences, Inc. from September 2021 to April 2024, focusing on product lifecycle decisions for clinical development. From February 2019 to September 2021, Katie led global Oncology insights and analytics at Gilead Sciences as Senior Director. Before that, Katie was Director of Commercial Analytics, Market Planning, & Competitive Intelligence at Halozyme Therapeutics, where responsibilities included market forecasting for a key oncology product launch. In the earlier career, Katie established the Market Intelligence function at Counsyl as Senior Director. Educational credentials include an MBA in Strategic Management, Entrepreneurship, and Marketing from The University of Chicago Booth School of Business and a BA in International Relations and Economics from Wellesley College.